Our pipeline is shaped by understanding cancer pathways, treatments designed with pharmacological properties to match disease need, and clinical strategies with clear rationale. https://t.co/wwZRfyJQ2f
October is #BreastCancerAwareness Month. At Merrimack, we stand with everyone who has been affected by this disease and we will continue to work to develop new treatments. #BCAM
At Merrimack, innovation is at our core. Want to help us answer the tough questions? Explore our open positions and join our team today: https://t.co/iv4Swr6nWi
Meet Daryl Drummond, Ph.D., our Head of Research. Daryl is a principal inventor for many of our nanotechnology-based candidates. https://t.co/W7CcQzGL8X
In case you missed our paper in @scisignal, we recently developed a multi-scale computational model that quantitatively links chemotherapy-induced DNA damage response signaling to cell fate. Read more here: https://t.co/1XBIxE7gTZ
Today we announced the completion of enrollment in our randomized Phase 2 clinical trial evaluating our lead investigational drug candidate, MM-121, in patients with heregulin positive non-small cell lung cancer. See the full release: https://t.co/4UVWE5565D
Innovation is at our core and we've built our culture on cooperation and collaboration. Learn more about our team and explore open career opportunities: https://t.co/OxT57TOfRP
A cornerstone of our development strategy is to establish efficacy through clinical studies in biomarker-enriched patient populations. Learn more about our ongoing studies:Γ https://t.co/6zPFtZNtOE
We're developing a new generation of treatments for #cancer through a focused pipeline of precise, targeted therapies. Discover more: https://t.co/9H51iikmHB
Check out our paper in @scisignal exploring a multi-scale computational model we developed that quantitatively links chemotherapy-induced DNA damage response signaling to cell fate. https://t.co/TmIr7PXiHR
Our programs are backed by our systems biology expertise and a clear clinical rationale. Explore our published research and presentations: https://t.co/9H51iikmHB